بررسی تاثیر شلاتورهای آهن بر بتا دو میکروگلوبولین ادرار وسدیم سرم بیماران مبتلا به تالاسمی ماژور

[1] Muncie Jr HL, Campbell JS. Alpha and beta thalassemia. American family physician. 2009 Aug 15;80(4):339-44. [PMID]
[2] Nienhuis AW, Nathan DG. Pathophysiology and clinical manifestations of the β-thalassemias. Cold Spring Harbor perspectives in medicine. 2012 Dec;2(12). [10.1101/csh perspect.a011726 ] [PMID]
[3] Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. The Lancet. 2018 Jan 13;391(10116):155-67. [10.1016/S0140-6736(17)31822-6] [PMID]
[4] Chowdhury PK, Saha M, Basu A, Chowdhury D, kumar Jena R. Profile of Iron Overload in Nontransfusion Dependent Hb E Beta Thalassaemia Patients-Is It Different?. Blood. 2015 Dec 3;126(23):4557. [ Link]
[5] Taher AT, Saliba AN. Iron overload in thalassemia: different organs at different rates. Hematology 2014, the American Society of Hematology Education Program Book. 2017 Dec 8;2017(1):265-71. [10.1182/asheducation-2017.1.265 ] [PMID]
[6] Saito H. Metabolism of iron stores. Nagoya journal of medical science. 2014 Aug;76(3-4):235. [PMID]
[7] Economou M, Printza N, Teli A, Tzimouli V, Tsatra I, Papachristou F, Athanassiou-Metaxa M. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. Acta haematologica. 2010 Apr 1;123(3):148-52.
[10.1159/000287238 ] [PMID]
[8] Borgna-Pignatti C, Marsella M. Iron chelation in thalassemia major. Clinical therapeutics. 2015 Dec 1;37(12):2866-77. [10.1016/j.clinthera.2015.10.001 ] [PMID]
[9] Hamed EA, ElMelegy NT. Renal functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective study. Italian journal of pediatrics. 2010 Dec;36:1-0. [10.1186/1824-7288-36-39 ] [PMID]
[10] Wei HY, Yang CP, Cheng CH, Lo FS. Fanconi syndrome in a patient with β‐thalassemia major after using deferasirox for 27 months. Transfusion. 2011 May;51(5):949-54. [10.1111/j. 1537-2995.2010.02939.x ] [PMID]
[11] Rheault MN, Bechtel H, Neglia JP, Kashtan CE. Reversible Fanconi syndrome in a pediatric patient on deferasirox. Pediatric blood & cancer. 2011 Apr;56(4):674-6. [10.1002/ pbc.22711 ] [PMID]
[12] Badeli H, Baghersalimi A, Eslami S, Saadat F, Rad AH, Basavand R, Papkiadeh SR, Darbandi B, Kooti W, Peluso I. Early kidney damage markers after deferasirox treatment in patients with thalassemia major: a case-control study. Oxidative Medicine and Cellular Longevity. 2019 Apr 21;2019. [10.1155/2019/ 5461617 ] [PMID]
[13] Zafari M, Aghamohammady A. Comparison of Beta-2 Microglobulin Level and Some Variables Between Thalassemia Major Patients Who Treated by Desferal and Control Group. Zahedan Journal of Research in Medical Sciences. 2017 Oct 31;19(10). [Link]
[14] Lapatsanis P, Sbyrakis S, Vretos C, Karaklis A, Doxiadis S. Phosphaturia in thalassemia. Pediatrics. 1976 Dec 1;58(6):885-92. [PMID]
[15] Aldudak B, Bayazit AK, Noyan A, Özel A, Anarat A, Sasmaz I,
Kilinç Y, Gali E, Anarat R, Dikmen N. Renal function in pediatric patients with β-thalassemia major. Pediatric nephrology. 2000 Oct;15:109-12. [10.1007/s004670000434] [PMID]
[16] VOLTI SL DGF, SCHILIRÒ G. Acute changes in renal function associated with deferoxamine therapy. Am J Dis Children. 1990:144(10):1069-70. [Link]
[17] Koren G, Bentur Y, Strong D, Harvey E, Klein J, Baumal R, Spielberg SP, Freedman MH. Acute changes in renal function associated with deferoxamine therapy. American Journal of Diseases of Children. 1989 Sep 1;143(9):1077-80. [10.1001/ archpedi.1989.02150210113029 ] [PMID]
[18] Rigalleau V, Beauvieux MC, Lasseur C, Chauveau P, Raffaitin C, Perlemoine C, Barthe N, Combe C, Gin H. The combination of cystatin C and serum creatinine improves the monitoring of kidney function in patients with diabetes and chronic kidney disease. Clinical chemistry. 2007 Nov 1;53(11):1988-9. [10. 1373/clinchem.2007.092171 ] [PMID]